EASTON BIOPHARMACEUTICALS: The hydrochloride of Nafamostat mesylate orally disintegrating tablets has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.EASTON BIOPHARMACEUTICALS recently obtained the drug registration certificate for hydrochloride nafurafine orally disintegrating tablets approved by the National Medical Products Administration. This drug is mainly used to improve pruritus in patients undergoing hemodialysis. Hydrochloride nafurafine is classified as a Class II psychotropic drug, and its approval is considered equivalent to passing the consistency evaluation. The product meets the drug registration requirements and is expected not to have a significant impact on the company's recent performance
According to the Zhitong Finance APP, EASTON BIOPHARMACEUTICALS (688513.SH) announced that it recently received the drug registration certificate for buprenorphine hydrochloride orally disintegrating tablets approved and issued by the National Medical Products Administration (referred to as "NMPA"). The main active ingredient of buprenorphine hydrochloride orally disintegrating tablets is buprenorphine hydrochloride, which is classified as a Class II psychotropic drug according to the National Regulations on the Administration of Narcotic Drugs and Psychotropic Substances. The indication is for the improvement of pruritus in patients undergoing hemodialysis (limited to cases where existing treatment is not effective).
The company's buprenorphine hydrochloride orally disintegrating tablets are registered and declared as Class 4 chemical drugs, and approval is considered equivalent to passing the consistency evaluation. The approval of this drug indicates that the product meets the relevant requirements for drug registration and will not have a significant impact on the company's recent performance